Rodman & Renshaw reiterated its Enzo Biochem ENZ Market Outperform and $7 price target in a research report published today.
In the report, Rodman & Renshaw states, "In keeping with our thesis, we believe there exists potential for additional
novel diagnostic tests such as ColonSentry and HPV OncoTect to be in-licensed in 2011 and 2012. Enzo has the potential to generate value for the long-term investor interested in a fundamental revenue story."
Shares of Enzo Biochem were trading at $3.71 at the time of posting, reflecting no change from Thursday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in